Research Article
The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
Table 2
Outcomes of stage IV, mutant EGFR lung adenocarcinoma patients who received 2nd-line versus 1st-line chemotherapy.
| | Outcome | 1st TKIs/2nd chemotherapy | 1st chemotherapy/2nd TKIs | value | | |
| | Response to 1st-line treatment, (%) | | | | | Disease control (PR + SD) | 45 (81.8%) | 50 (89.3%) | 0.26 | | PR | 30 (54.5%) | 23 (41.7%) | 0.16 | | SD | 15 (27.3%) | 27 (47.6%) | 0.02 | | PD | 10 (18.2%) | 6 (10.7%) | 0.26 | | Patients received 2nd-line treatment | 27 (49.1%) | 52 (92.9%) | <0.0001 |
| | | | | |
| | Response to 2nd-line treatment, (%) | | | | | Disease control (PR + SD) | 12 (44.4%) | 37 (71.2%) | 0.02 | | PR | 3 (11.1%) | 13 (25%) | 0.15 | | SD | 9 (33.3%) | 24 (46.2%) | 0.27 | | PD | 15 (55.6%) | 15 (28.8%) | 0.02 | | Survival time, days, median (IQR) | | | | | OS | 390 (254–499) | 662 (342–773) | <0.0001 | | PFS to 1st-line treatment | 188 (102–276) | 214 (142–310) | 0.06 | | PFS to 2nd-line treatment | 85 (59–148) | 199 (67–354) | <0.0001 |
|
|
IQR: interquartile range; PR; partial response; SD: stable disease; PD: progressive disease; OS: overall survival time; PFS: progression-free survival.
|
